SCHEMBL5113349

SCHEMBL5113349

O=C(Nc1c[nH]nc1-c1nc2cc[nH]c(=O)c2[nH]1)c1c(F)cccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.37
AURKB Q96GD4 2/20 0.35
AURKA O14965 1/20 0.35
HTT P42858 2/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
NOD2 Q9HC29 1/20 0.34
CDK1 P06493 4/20 0.34
CDK2 P24941 4/20 0.34
CCNB1 P14635 3/20 0.34
CCNA2 P20248 3/20 0.34
ROCK1 Q13464 2/20 0.34
CLK4 Q9HAZ1 2/20 0.34
STK17A Q9UEE5 2/20 0.34
CCNA1 P78396 1/20 0.34
DYRK3 O43781 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646113 0.83 MAPT (0.41) MAPTMEN1KMT2ALMNAAURKB
SCHEMBL1646494 0.80 MAPT (0.60) MAPTMEN1KMT2ALMNAAURKB
SCHEMBL8302422 0.79 MEN1 (0.41) MAPTMEN1KMT2ALMNAAURKB
SCHEMBL12252539 0.79 MAPT (0.48) MAPTMEN1KMT2AAURKBHTT
SCHEMBL1645364 0.78 MAPT (0.48) MAPTMEN1KMT2ALMNAHTT
SCHEMBL3586136 0.77 MEN1 (0.43) MAPTMEN1KMT2ALMNAAURKB
SCHEMBL1645923 0.77 PRSS12 (0.49) MAPTMEN1KMT2AABL1ALDH1A1
SCHEMBL8305324 0.77 MAPT (0.46) MAPTMEN1KMT2AHTTIRAK4
SCHEMBL1647120 0.77 MAPT (0.48) MAPTMEN1KMT2AHTTCDK1
SCHEMBL1646344 0.77 MAPT (0.46) MAPTMEN1KMT2ALMNAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B MAPT 1805/4885MEN1 2227/4885KMT2A 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.